Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT05267990
Enrolling by invitation Not applicable

Coronary Artery Calcium-guided Primary Prevention of Major Coronary Heart Disease in Asymptomatic Diabetes

NCT05267990 · tracked via the Priya Life Science Taiwan tracker
Sponsor
JuFeng, Hsiao
Phase
Not applicable
Started
2022-03-01
Last updated
2022-05-06

Condition(s) studied

Type2 DiabetesCoronary Heart Disease

Investigational drug(s) / intervention(s)

Multi-Detector Computed Tomography

Multi-Detector Computed Tomography: Coronary angiography calcium score via Multi-Detector Computed Tomography

Study summary

To evaluate benefits of primary prevention of major coronary heart disease for asymptomatic coronary artery disease in type 2 diabetes mellitus based on the coronary artery calcium score Our proposal

1. Based on CAC score, primary early prevention could reduce incidence of major coronary heart disease (CHD) including cardiac mortality, acute myocardial infarction, coronary revascularization
2. based on CAC score, primary early prevention could reduce all cause mortality, cardiac mortality, cardiovascular disease, heart failure, ischemic stroke, heart failure associated hospitalization and chronic kidney disease and related clinical cost effect

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: more than 40 years old T2DM patients have any one cardiovascular risk as follows 1. total cholesterol\>200mg/dl or low density lipoprotein (LDL) \>100mg/dl 2. blood pressure\>140/90mm/Hg or taking anti-hypertension agents 3. history of smoking 4. family history of early coronary heart diseases 5. proteinuria Exclusion Criteria: history of cardiovascular diseases such as coronary heart disease, stroke, heart failure etc, pregnant

Primary outcome measure(s)

  • rate of major coronary heart disease — 5-year followup
    cardiac mortality, acute myocardial infarction and coronary revascularization

Trial sites (1)

FacilityCityRegionStatus
Lo-Tung Poh-Ai Hospital Yilan Taiwan

Other trials for the same condition

Mindfulness-based Interventions on Psychophysiological Recovery and Physical Functioning After Coronary Heart Surgery Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05267990 on ClinicalTrials.gov ↗ ← All trials in Taiwan